DelveInsight’s “Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Irritable Bowel Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Irritable Bowel Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Irritable Bowel Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Irritable Bowel Syndrome: An Overview
Irritable bowel syndrome is a chronic functional bowel disease characterized by symptoms of abdominal pain and/or discomfort associated with altered bowel habits in the absence of a structural or organic cause. Based on bowel patterns at a particular point in time, the disorder may be categorized into four groups: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), mixed (IBS-M), and un-subtyped.
The precise cause of irritable bowel syndrome remains unknown. However, several factors have been implicated in the pathophysiology of irritable bowel syndrome symptoms, including genetic disposition, diet, intestinal microbiota, and low-grade mucosal inflammation. No specific biomarker related to irritable bowel syndrome has been found. Multiple risk factors have been strongly associated with irritable bowel syndrome development, including young age, tobacco smoking, and mental health disorders, mainly stress and anxiety.
Irritable Bowel Syndrome Market Key Facts
Among EU4 countries, Germany accounted for the maximum market size in 2022.
By 2032, among all the emerging therapies, the highest revenue is expected to be generated by Blautix, followed by RHB-102, and Aldafermin in the 7MM.
The total prevalent cases of Irritable Bowel Syndrome in the United States were around 14,410,000 cases in 2022.
The US contributed to the largest prevalent population of Irritable Bowel Syndrome, acquiring ~46% of the 7MM in 2022. Whereas, Japan accounted for around 12% and Germany accounted for around 11% of the total population share, respectively, in 2022.
Among EU4 countries, Germany accounted for the largest number of Irritable Bowel Syndrome cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
According to DelveInsight estimates, there were around 2,522,000, 2,234,000, 2,053,000, and 396,000 in diarrhea-predominant, mixed stool pattern, constipation-predominant, and unspecified irritable bowel syndrome, respectively in the United States in 2022. These cases are projected to increase during the forecasted period.
In the 7MM, approximately 33% of the patient share is attributed to males, whereas only 67% of females suffer from Irritable Bowel Syndrome.
The diagnosis and treatment rate of Irritable Bowel Syndrome is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of Irritable Bowel Syndrome, thus leading to an increase in awareness among patients and clinicians.
Key players such as 4D Pharma (blautix), Cosmo Pharmaceuticals (rifamycin SV-MMX), RedHill Biopharma (RHB-102), Seed Health (DS-01), NGM Pharmaceuticals (aldafermin), and several others are evaluating their lead candidates in different stages of clinical development to improve the Irritable Bowel Syndrome treatment outlook.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Irritable Bowel Syndrome pipeline therapies. It also thoroughly assesses the Irritable Bowel Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Irritable Bowel Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Irritable Bowel Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Irritable Bowel Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Irritable Bowel Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Irritable Bowel Syndrome Epidemiology, Segmented as –
Total Diagnosed Prevalent Cases of Irritable Bowel Syndrome
Severity-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome
Total Treated Cases of Irritable Bowel Syndrome
Gender-specific Prevalent Cases of Irritable Bowel Syndrome
Total Prevalent Cases of Irritable Bowel Syndrome
Subtype-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome
Age-specific Prevalent Cases of Irritable Bowel Syndrome
Irritable Bowel Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Irritable Bowel Syndrome market or expected to be launched during the study period. The analysis covers the Irritable Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Irritable Bowel Syndrome drugs based on their sale and market share.
The report also covers the Irritable Bowel Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Irritable Bowel Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Irritable Bowel Syndrome Market Will Evolve and Grow by 2032 @
Irritable Bowel Syndrome Therapeutics Analysis
Treatment of irritable bowel syndrome consists of stress relief, change in diet, proper medicines, and counseling. Medications for treating irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others. Furthermore, antispasmodics are also used to treat irritable bowel syndrome, including dicyclomine, peppermint oil, and hyoscyamine.
Several major pharma and biotech companies are developing therapies for Irritable bowel syndrome. Currently, OrphoMed is leading the therapeutics market with its Irritable bowel syndrome drug candidates in the most advanced stage of clinical development. The dynamics of the irritable bowel syndrome market are anticipated to change in the coming years owing to the emerging pipeline raising awareness of the diseases, and incremental healthcare spending worldwide.
Irritable Bowel Syndrome Companies Actively Working in the Therapeutics Market Include
Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, Metacrine, MGC Pharma, Napo Pharmaceuticals, Novome Biotechnologies, Renexxion, Sentia Medical Sciences, Serentrix LLC, Vitality Biopharma, and many others.
Emerging and Marketed Irritable Bowel Syndrome Therapies Covered in the Report Include:
Blautix: 4D Pharma
Blautix (MRx1234): 4D pharma
Rifamycin SV-MMX: Cosmo Pharmaceuticals
VIBERZI/TRUBERZI (eluxadoline): Abbvie
LINZESS/CONSTELLA (linaclotide): Ironwood Pharmaceuticals/ Abbvie/ Astellas Pharma
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Irritable Bowel Syndrome Competitive Intelligence Analysis
4. Irritable Bowel Syndrome Market Overview at a Glance
5. Irritable Bowel Syndrome Disease Background and Overview
6. Irritable Bowel Syndrome Patient Journey
7. Irritable Bowel Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Irritable Bowel Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Irritable Bowel Syndrome Unmet Needs
10. Key Endpoints of Irritable Bowel Syndrome Treatment
11. Irritable Bowel Syndrome Marketed Therapies
12. Irritable Bowel Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Irritable Bowel Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Irritable Bowel Syndrome Market Outlook (In US, EU5, and Japan)
16. Irritable Bowel Syndrome Companies Active in the Market
17. Irritable Bowel Syndrome Access and Reimbursement Overview
18. KOL Views on the Irritable Bowel Syndrome Market
19. Irritable Bowel Syndrome Market Drivers
20. Irritable Bowel Syndrome Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chemotherapy Induced Neutropenia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States